TP53 and prostate carcinoma: In opposition to p53, c‐Myc represses mir‐34a transcription by binding to the conserved promoter region of mir‐34a (Chang et al. 2008), suggesting c‐Myc drives prostate cancer progression by the inhibition of mir‐34a.